LAKEFRONT
LIVE

Serial Number

99261757

Owner

Galapagos NV

Attorney

Alexandra MacKay

Filing Date

Jul 1, 2025

Add to watchlist:

No watchlists yet
View on USPTO

LAKEFRONT Trademark

Serial Number: 99261757 • Registration: 8238979

LAKEFRONT is a trademark filed by Galapagos NV on July 1, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Galapagos NV (19 trademarks)

Mechelen B-2800 , BE

Entity Type: 03

Trademark Details

Filing Date

July 1, 2025

Registration Date

May 5, 2026

Published for Opposition

March 17, 2026

Goods & Services

Medical and scientific research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the, examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely, configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; pharmaceutical drug development services

Medical services; Medical advisory services; Medical and pharmaceutical consultation; Pharmaceutical advice

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 5, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 5, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 17, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 19, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 18, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 18, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 19, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 19, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 19, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 19, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 1, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 1, 2025 NWOS
NEW APPLICATION ENTERED
Jul 1, 2025 NWAP